- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Lupin has announced a board meeting to approve the financial results for the quarter and half-year. The company received U.S. FDA approval for Prucalopride Tablets (1 mg and 2 mg), bioequivalent to Takeda’s Motegrity®, with U.S. sales around USD 184 million annually. Manufactured at Lupin’s Goa facility, this approval expands Lupin’s presence in the U.S. gastrointestinal segment and could boost its specialty portfolio and revenue mix.